Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P.

Sci Transl Med. 2019 May 8;11(491). pii: eaat7838. doi: 10.1126/scitranslmed.aat7838. Epub 2019 May 1.

PMID:
31043521
2.

In Search of Biomarkers for Autism Spectrum Disorder.

Del Valle Rubido M, McCracken JT, Hollander E, Shic F, Noeldeke J, Boak L, Khwaja O, Sadikhov S, Fontoura P, Umbricht D.

Autism Res. 2018 Nov;11(11):1567-1579. doi: 10.1002/aur.2026. Epub 2018 Oct 15.

3.

Nailing the Right Dose! The Key for Developing Glycine Transporter Inhibitors for Schizophrenia.

Umbricht D.

Biol Psychiatry. 2018 Sep 15;84(6):394-395. doi: 10.1016/j.biopsych.2018.07.006. No abstract available.

PMID:
30165949
4.

Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.

Pinard E, Borroni E, Koerner A, Umbricht D, Alberati D.

Chimia (Aarau). 2018 Aug 22;72(7):477-484. doi: 10.2533/chimia.2018.477.

PMID:
30158010
5.

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.

Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Bækvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschøn HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodríguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretzschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O'Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB, Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamon GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F; eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Müller-Myhsok B, Nordentoft M, Nöthen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx BWJH, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Völzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Børglum AD, Sullivan PF; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium.

Nat Genet. 2018 May;50(5):668-681. doi: 10.1038/s41588-018-0090-3. Epub 2018 Apr 26.

6.

Cerebral blood flow predicts differential neurotransmitter activity.

Dukart J, Holiga Š, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro F.

Sci Rep. 2018 Mar 6;8(1):4074. doi: 10.1038/s41598-018-22444-0.

7.

Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.

Fraguas D, Díaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C.

Schizophr Bull. 2019 Jan 1;45(1):57-68. doi: 10.1093/schbul/sbx192.

PMID:
29370436
8.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1924. doi: 10.1038/npp.2017.92.

9.

Placebo Response and Practice Effects in Schizophrenia Cognition Trials.

Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D.

JAMA Psychiatry. 2017 Aug 1;74(8):807-814. doi: 10.1001/jamapsychiatry.2017.1574.

10.

Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.

Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE.

Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.

PMID:
28433500
11.

An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.

Direk N, Williams S, Smith JA, Ripke S, Air T, Amare AT, Amin N, Baune BT, Bennett DA, Blackwood DHR, Boomsma D, Breen G, Buttenschøn HN, Byrne EM, Børglum AD, Castelao E, Cichon S, Clarke TK, Cornelis MC, Dannlowski U, De Jager PL, Demirkan A, Domenici E, van Duijn CM, Dunn EC, Eriksson JG, Esko T, Faul JD, Ferrucci L, Fornage M, de Geus E, Gill M, Gordon SD, Grabe HJ, van Grootheest G, Hamilton SP, Hartman CA, Heath AC, Hek K, Hofman A, Homuth G, Horn C, Jan Hottenga J, Kardia SLR, Kloiber S, Koenen K, Kutalik Z, Ladwig KH, Lahti J, Levinson DF, Lewis CM, Lewis G, Li QS, Llewellyn DJ, Lucae S, Lunetta KL, MacIntyre DJ, Madden P, Martin NG, McIntosh AM, Metspalu A, Milaneschi Y, Montgomery GW, Mors O, Mosley TH Jr, Murabito JM, Müller-Myhsok B, Nöthen MM, Nyholt DR, O'Donovan MC, Penninx BW, Pergadia ML, Perlis R, Potash JB, Preisig M, Purcell SM, Quiroz JA, Räikkönen K, Rice JP, Rietschel M, Rivera M, Schulze TG, Shi J, Shyn S, Sinnamon GC, Smit JH, Smoller JW, Snieder H, Tanaka T, Tansey KE, Teumer A, Uher R, Umbricht D, Van der Auwera S, Ware EB, Weir DR, Weissman MM, Willemsen G, Yang J, Zhao W, Tiemeier H, Sullivan PF.

Biol Psychiatry. 2017 Sep 1;82(5):322-329. doi: 10.1016/j.biopsych.2016.11.013. Epub 2016 Dec 8.

12.

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU.

Am J Psychiatry. 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503. Epub 2016 Dec 6. Review.

13.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.

Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.

Neuropsychopharmacology. 2017 Aug;42(9):1914-1923. doi: 10.1038/npp.2016.232. Epub 2016 Oct 6. Erratum in: Neuropsychopharmacology. 2017 Aug;42(9):1924.

14.

Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison.

Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM.

J Clin Psychiatry. 2016 May;77(5):628-34. doi: 10.4088/JCP.13m08351.

PMID:
27035871
15.

Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.

Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R.

Qual Life Res. 2016 Jan;25(1):201-11. doi: 10.1007/s11136-015-1057-9. Epub 2015 Jul 5.

PMID:
26143058
16.

Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome.

Simon AE, Umbricht D, Lang UE, Borgwardt S.

Schizophr Res. 2014 Nov;159(2-3):292-8. doi: 10.1016/j.schres.2014.09.016. Epub 2014 Sep 26. Review.

17.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.

JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.

PMID:
24696094
18.

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.

Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L.

Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. Epub 2014 Jan 27.

19.

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.

Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J.

Schizophr Res. 2013 Nov;150(2-3):328-33. doi: 10.1016/j.schres.2013.07.058. Epub 2013 Sep 9. Review.

PMID:
24028744
20.

Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, Gomez Mancilla B, Sovago J, Buck A, Hasler G.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):737-42. doi: 10.1073/pnas.1210984110. Epub 2012 Dec 17.

21.

Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers.

Martin-Facklam M, Pizzagalli F, Zhou Y, Ostrowitzki S, Raymont V, Brašić JR, Parkar N, Umbricht D, Dannals RF, Goldwater R, Wong DF.

Neuropsychopharmacology. 2013 Feb;38(3):504-12. doi: 10.1038/npp.2012.212. Epub 2012 Nov 7.

22.

Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome.

Simon AE, Grädel M, Cattapan-Ludewig K, Gruber K, Ballinari P, Roth B, Umbricht D.

Schizophr Res. 2012 Dec;142(1-3):108-15. doi: 10.1016/j.schres.2012.09.004. Epub 2012 Sep 29.

PMID:
23025995
23.

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.

Goeldner C, Ballard TM, Knoflach F, Wichmann J, Gatti S, Umbricht D.

Neuropharmacology. 2013 Jan;64:337-46. doi: 10.1016/j.neuropharm.2012.08.001. Epub 2012 Aug 23. Review.

PMID:
22992331
24.

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.

Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D.

Schizophr Bull. 2012 Sep;38(5):958-66. doi: 10.1093/schbul/sbs069. Review.

25.

Translating glutamate: from pathophysiology to treatment.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM.

Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804. Review.

26.

Ultra high-risk state for psychosis and non-transition: a systematic review.

Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L.

Schizophr Res. 2011 Oct;132(1):8-17. doi: 10.1016/j.schres.2011.07.002. Epub 2011 Jul 23. Review.

PMID:
21784618
27.

Primary care and the early phases of schizophrenia in the Czech Republic.

Holub D, Wenigová B, Umbricht D, Simon AE.

Epidemiol Psichiatr Soc. 2010 Jul-Sep;19(3):243-50.

PMID:
21261220
28.

Prodromal schizophrenia in primary care: a randomised sensitisation study.

Simon AE, Jegerlehner S, Müller T, Cattapan-Ludewig K, Frey P, Grossenbacher M, Seifritz E, Umbricht D.

Br J Gen Pract. 2010 Sep;60(578):e353-9. doi: 10.3399/bjgp10X515377.

29.

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR.

Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.

30.

High remission rates from an initial ultra-high risk state for psychosis.

Simon AE, Umbricht D.

Schizophr Res. 2010 Feb;116(2-3):168-72. doi: 10.1016/j.schres.2009.10.001. Epub 2009 Oct 24.

PMID:
19854621
31.

Is elevated striatal dopamine function a prodromal sign of schizophrenia?

Simon AE, Umbricht D.

Arch Gen Psychiatry. 2009 Aug;66(8):916-7. doi: 10.1001/archgenpsychiatry.2009.100. No abstract available.

PMID:
19652133
32.

Subclinical hallucinations in adolescent outpatients: an outcome study.

Simon AE, Cattapan-Ludewig K, Gruber K, Ouertani J, Zimmer A, Roth B, Isler E, Umbricht D.

Schizophr Res. 2009 Mar;108(1-3):265-71. doi: 10.1016/j.schres.2008.12.018. Epub 2009 Jan 22.

PMID:
19167194
33.

The International Study on General Practitioners and Early Psychosis (IGPS).

Simon AE, Lester H, Tait L, Stip E, Roy P, Conrad G, Hunt J, Epstein I, Larsen TK, Amminger P, Holub D, Wenigová B, Turner M, Berger GE, O'Donnell C, Umbricht D.

Schizophr Res. 2009 Mar;108(1-3):182-90. doi: 10.1016/j.schres.2008.11.004. Epub 2008 Dec 16.

PMID:
19087897
34.

[On the front line: survey on shared responsibility. General practitioners and schizophrenia].

Stip E, Boyer R, Sepehry AA, Rodriguez JP, Umbricht D, Tempier A, Simon AE.

Sante Ment Que. 2007 Spring;32(1):281-97. French.

PMID:
18253672
35.

Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function.

Bickel S, Lipp HP, Umbricht D.

Neuropsychopharmacology. 2008 Jun;33(7):1680-9. Epub 2007 Aug 22.

36.

Cognitive functioning in the schizophrenia prodrome.

Simon AE, Cattapan-Ludewig K, Zmilacher S, Arbach D, Gruber K, Dvorsky DN, Roth B, Isler E, Zimmer A, Umbricht D.

Schizophr Bull. 2007 May;33(3):761-71. Epub 2007 Apr 4.

37.

Impaired attentional modulation of auditory evoked potentials in N-methyl-D-aspartate NR1 hypomorphic mice.

Bickel S, Lipp HP, Umbricht D.

Genes Brain Behav. 2007 Aug;6(6):558-68. Epub 2006 Nov 17.

38.

Help-seeking pathways in early psychosis.

Platz C, Umbricht DS, Cattapan-Ludewig K, Dvorsky D, Arbach D, Brenner HD, Simon AE.

Soc Psychiatry Psychiatr Epidemiol. 2006 Dec;41(12):967-74. Epub 2006 Oct 11.

39.

Developing services for the early detection of psychosis: a critical consideration of the current state of the art.

Simon AE, Roth B, Zmilacher S, Isler E, Umbricht D.

Eur Child Adolesc Psychiatry. 2007 Mar;16(2):96-103. Epub 2006 Sep 8. Review.

PMID:
16964451
40.

Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia.

Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC.

Biol Psychiatry. 2006 Apr 15;59(8):762-72. Epub 2006 Feb 21.

PMID:
16497277
41.

Defining subjects at risk for psychosis: a comparison of two approaches.

Simon AE, Dvorsky DN, Boesch J, Roth B, Isler E, Schueler P, Petralli C, Umbricht D.

Schizophr Res. 2006 Jan 1;81(1):83-90. Epub 2005 Nov 16.

PMID:
16297599
42.

General practitioners and schizophrenia: results from a Swiss survey.

Simon AE, Lauber C, Ludewig K, Braun-Scharm H, Umbricht DS; Swiss Early Psychosis Project.

Br J Psychiatry. 2005 Sep;187:274-81.

PMID:
16135866
43.

Mismatch negativity in schizophrenia: a meta-analysis.

Umbricht D, Krljes S.

Schizophr Res. 2005 Jul 1;76(1):1-23. Epub 2005 Jan 23.

PMID:
15927795
44.

Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?

Umbricht D, Vyssotki D, Latanov A, Nitsch R, Lipp HP.

Clin Neurophysiol. 2005 Feb;116(2):353-63.

PMID:
15661113
45.

Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans.

Umbricht D, Vyssotky D, Latanov A, Nitsch R, Brambilla R, D'Adamo P, Lipp HP.

Brain Res. 2004 Sep 3;1019(1-2):189-200.

PMID:
15306253
46.

How specific are deficits in mismatch negativity generation to schizophrenia?

Umbricht D, Koller R, Schmid L, Skrabo A, Grübel C, Huber T, Stassen H.

Biol Psychiatry. 2003 Jun 15;53(12):1120-31.

PMID:
12814863
47.

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM.

Neuron. 2003 May 22;38(4):547-54.

48.

Atypical antipsychotics in the treatment of schizophrenia.

Bridler R, Umbricht D.

Swiss Med Wkly. 2003 Feb 8;133(5-6):63-76. Review.

49.
50.

Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease.

Wollmer MA, Papassotiropoulos A, Streffer JR, Grimaldi LM, Kapaki E, Salani G, Paraskevas GP, Maddalena A, de Quervain D, Bieber C, Umbricht D, Lemke U, Bosshardt S, Degonda N, Henke K, Hegi T, Jung HH, Pasch T, Hock C, Nitsch RM.

Psychiatr Genet. 2002 Sep;12(3):155-60.

PMID:
12218659

Supplemental Content

Loading ...
Support Center